Clinical evidence on the safety of NMN released recently

      Researchers from Keio University and Washington University published a new article on Endocrine Journal.

      The safety of single dose at 100, 250, and 500 mg NMN was investigated in 10 Japanese men.

      Clinical findings and parameters, and the pharmacokinetics of NMN metabolites were investigated for 5 h after each intervention.

      The study concluded that the single oral administration of NMN was safe and effectively metabolized in healthy men without causing any significant deleterious effects. Thus, the oral administration of NMN was found to be feasible, implicating a potential therapeutic strategy to mitigate aging-related disorders in humans[1].

      The study is just the start of a series of clinical studies on NMN and it proved NMN’s safety to some extent.

      However, due to the lack of a control group and the small sample size, further studies will be needed. Besides, the safety of repeated-dose on humans remains to be confirmed.

      The clinical study on UTHEVERTM would somehow further confirms NMN’s safety on repeated dose with placebo group. The sample size would be 66 which is more convincing.

      Reference

      1. Junichiro Irie, etc. Effect of oral administration of nicotinamide mononucleotide on clinical parameters and nicotinamide metabolite levels in healthy Japanese men, Endocine Journal, 2020, 67 (2), 153-160
  • Effepharm started new clinical trials on Uthever™ as

    Effepharm started our new clinical trials on UtheverTM NMN ingredient recently. According to ICTRP ( International Clinical Trials Registry Platform),  the clinical trial on UtheverTM is the largest scale trial on NMN in the world. What’s more, Effepham is the first and the...
  • Effepharm announced acquisitions and new R&D center establishment

    Effepharm acquired two bio-pharmaceutical companies recently, named Dendrimer Co. and Folvo Co., the acquisition has significantly enhanced our R&D capability in anti-aging and energy metabolism. Also Effepharm’s new R&D center is established. Effepharm’s new R&D center will focus on new pharmaceutical...
  • Effepharm team at ”Hi Japan”

      From 2nd to 4th Oct 2019, Effepharm team participated in Hi Japan Exhibit, the Largest Trade Show for Functional & Health Ingredients in Japan. Effepharm is in line with the purpose of this event. Its Highlights: not only the food...
  • Effepharm team in the Vitafoods Europe 2019

    On 7th May, 2019, Sales team at Effepharm came to vitafoods with latest products and new technology. Booth Position:Sliver Area  No. N189 NMN- Popular NAD+ Precursors CBD- This ingredient is very popular in many Europe countries. Effepharm’s R&D has scheduled...
  • New Laboratory has been completed!

    Effepharm Ltd. currently not only holds a strong R&D team consisting of experienced  PHDs and Postdocs returned from abroad, but also employs senior professors and  scholars at home and abroad as a team of research consultants to help us optimize ...
  • Meet Us at the Vitafoods Europe 2019!

      May. 2019, Effepharm teams will participate in Vitafoods Europe 2019 Exhibit, a annual event where the global  nutraceutical supply chain come to gether to do business At that time, Effepharm teams will be waiting for your inquiry and cooperation...
  • “Once-in-two-lifetimes Ingredients”–NMN or NR?

    “Once-in-two-lifetimes Ingredients”--NMN or NR? Nowadays, the people all over the world spend billions of dollars on anti-aging products. While most anti-aging products try to reverse signs of aging on your skin, Nicotinamide Rboside aims to reverse signs of aging from inside your...
  • Sales Office transferred to Shanghai

    Sales Office transferred to Shanghai The sales office was transferred to Shanghai in 2017-EffePharm(Shanghai)Co.,Ltd At Effepharm, we apply science and technologies to improve health and well-being at every stage of life with innovative thinking. Our dedicated team strive to set...